[go: up one dir, main page]

WO2004067774A3 - Polymorphismes de nucleotide simple utilises en tant que diagnostics predictifs d'effet indesirable (adr) et d'efficacite d'un medicament - Google Patents

Polymorphismes de nucleotide simple utilises en tant que diagnostics predictifs d'effet indesirable (adr) et d'efficacite d'un medicament Download PDF

Info

Publication number
WO2004067774A3
WO2004067774A3 PCT/EP2004/000539 EP2004000539W WO2004067774A3 WO 2004067774 A3 WO2004067774 A3 WO 2004067774A3 EP 2004000539 W EP2004000539 W EP 2004000539W WO 2004067774 A3 WO2004067774 A3 WO 2004067774A3
Authority
WO
WIPO (PCT)
Prior art keywords
adr
single nucleotide
nucleotide polymorphisms
human subject
drug
Prior art date
Application number
PCT/EP2004/000539
Other languages
English (en)
Other versions
WO2004067774A2 (fr
Inventor
Udo Stropp
Stephan Schwers
Harald Kallabis
Original Assignee
Bayer Healthcare Ag
Udo Stropp
Stephan Schwers
Harald Kallabis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Udo Stropp, Stephan Schwers, Harald Kallabis filed Critical Bayer Healthcare Ag
Priority to EP04704556A priority Critical patent/EP1592808A2/fr
Publication of WO2004067774A2 publication Critical patent/WO2004067774A2/fr
Publication of WO2004067774A3 publication Critical patent/WO2004067774A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des méthodes diagnostiques et des kits comprenant des oligo et/ou des polynucléotides ou des dérivés associés, notamment des anticorps qui déterminent si un sujet humain présente un risque de subir les effets indésirables d'un médicament après un traitement par statines, si le sujet répond faiblement ou fortement au traitement, ou s'il métabolise bien ou pas les statines. L'invention concerne également des méthodes diagnostiques et des kits comprenant des anticorps qui déterminent si un sujet humain présente un risque pour une maladie cardiovasculaire. L'invention concerne en outre des séquences polymorphiques et d'autres gènes.
PCT/EP2004/000539 2003-01-31 2004-01-23 Polymorphismes de nucleotide simple utilises en tant que diagnostics predictifs d'effet indesirable (adr) et d'efficacite d'un medicament WO2004067774A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04704556A EP1592808A2 (fr) 2003-01-31 2004-01-23 Polymorphismes de nucleotide simple utilises en tant que diagnostics predictifs d'effet indesirable (adr) et d'efficacite d'un medicament

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP03002212.3 2003-01-31
EP03002212 2003-01-31
EP03002153.9 2003-02-03
EP03002153 2003-02-03

Publications (2)

Publication Number Publication Date
WO2004067774A2 WO2004067774A2 (fr) 2004-08-12
WO2004067774A3 true WO2004067774A3 (fr) 2004-10-21

Family

ID=32826771

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/000539 WO2004067774A2 (fr) 2003-01-31 2004-01-23 Polymorphismes de nucleotide simple utilises en tant que diagnostics predictifs d'effet indesirable (adr) et d'efficacite d'un medicament

Country Status (2)

Country Link
EP (1) EP1592808A2 (fr)
WO (1) WO2004067774A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007071382A2 (fr) * 2005-12-22 2007-06-28 Siemens Medical Solutions Diagnostics Gmbh Méthode pour prédire des réponses indésirable à un médicament
EP3765516A2 (fr) * 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Molécules multifonctionnelles et utilisations associées
CN115651978A (zh) * 2022-10-13 2023-01-31 解码（上海）生物医药科技有限公司 检测心血管药物疗效和副作用的基因试剂盒及制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1136554A1 (fr) * 2000-03-24 2001-09-26 Bayer Aktiengesellschaft Polymorphismes du gène codant le transporteur à cassette de fixation à l'ATP 1 (ABC1), et usages pour le diagnostique et le traitement de désordres lipidiques, de maladies cardiovasculaires et de maladies inflammatoires

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1136554A1 (fr) * 2000-03-24 2001-09-26 Bayer Aktiengesellschaft Polymorphismes du gène codant le transporteur à cassette de fixation à l'ATP 1 (ABC1), et usages pour le diagnostique et le traitement de désordres lipidiques, de maladies cardiovasculaires et de maladies inflammatoires

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 4 June 1995 (1995-06-04), HABETS ET AL.: "Human T-lymphomia invasion and metastasis inducing TIAM1 protein (TIAM1) mRNA, complete cds.", XP002279808, Database accession no. HS162961 *
DORNBROOK-LAVENDER KIMBERLY A ET AL: "Genetic polymorphisms in emerging cardiovascular risk factors and response to statin therapy.", CARDIOVASCULAR DRUGS AND THERAPY, vol. 17, no. 1, January 2003 (2003-01-01), pages 75 - 82, XP009030786, ISSN: 0920-3206 (ISSN print) *
HABETS G G M ET AL: "SEQUENCE OF THE HUMAN INVASION-INDUCING TIAM1 GENE, ITS CONSERVATION IN EVOLUTION AND ITS EXPRESSION IN TUMOR CELL LINES OF DIFFERENT TISSUE ORIGIN", ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 10, no. 7, 6 April 1995 (1995-04-06), pages 1371 - 1376, XP002039499, ISSN: 0950-9232 *
HWANG DAVID M ET AL: "A genome-based resource for molecular cardiovascular medicine: Toward a compendium of cardiovascular genes", CIRCULATION, AMERICAN HEART ASSOCIATION, DALLAS, TX, US, vol. 96, no. 12, 16 December 1997 (1997-12-16), pages 4146 - 4203, XP002197842, ISSN: 0009-7322 *
OHNISHI Y ET AL: "IDENTIFICATION OF 187 SINGLE NUCLEOTIDE POLYMORPHISMS (SNPS) AMONG 41 CANDIDATE GENES FOR ISCHEMIC HEART DISEASE IN THE JAPANESE POPULATION", HUMAN GENETICS, BERLIN, DE, vol. 106, 2000, pages 288 - 292, XP002949197, ISSN: 0340-6717 *
TURNER S T ET AL: "Antihypertensive pharmacogenetics: Getting the right drug into the right patient", JOURNAL OF HYPERTENSION, CURRENT SCIENCE, PHILADELPHIA, PA, US, vol. 19, no. 1, January 2001 (2001-01-01), pages 1 - 11, XP002241062, ISSN: 0263-6352 *

Also Published As

Publication number Publication date
EP1592808A2 (fr) 2005-11-09
WO2004067774A2 (fr) 2004-08-12

Similar Documents

Publication Publication Date Title
WO2003053223A3 (fr) Diagnostic du cancer de la prostate et prevision des resultats d'un traitement par analyse de l'expression genetique
WO2006048291A3 (fr) Technologie de micro-reseaux de transcriptome et procedes d'utilisation de celle-ci
JP2005515778A5 (fr)
AU2003207528A1 (en) Method of detecting t-cell proliferation for diagnosis of diseases by gene array
WO2006020269A3 (fr) Biomarqueurs de maladie neurodegenerative
WO2005040396A3 (fr) Systeme d'essai qrt-pcr pour le profilage d'expression genetique
WO2004111273A3 (fr) Marqueurs d'expression genique utilises en vue d'une reaction a des medicaments inhibiteurs de egfr
WO2002057414A3 (fr) Evaluation du niveau d'expression leucocytaire
CA2282746A1 (fr) Prediction de la coronaropathie
WO2004018709A3 (fr) Polymorphismes simple nucleotide utilises pour la prediction sensible d'effets indesirables et de l'efficacite d'un medicament
WO2004076682A3 (fr) Cibles destinees a reguler la croissance cellulaire et destinees a des methodes de diagnostic
AU2003233451A1 (en) Targets, methods, and reagents for diagnosis and treatment of schizophrenia
WO2000042905A3 (fr) Procede et dispositif de mesure quantitative non invasive d'analytes sanguins
WO2002102229A3 (fr) Methodes et necessaires servant a diagnostiquer une action cancerigene et a determiner la resistance aux effets anti-neoplasiques d'un traitement anti-oestrogene
WO2005048818A3 (fr) Procede de diagnostic d'une maladie renale
WO2003102216A3 (fr) Systemes multiplexes conçus pour le sequençage d'acide nucleique
WO2002092858A3 (fr) Technique de recherche de maladie
WO2002061144A3 (fr) Diagnostic de tumeur cerebrale et prediction de resultat de traitement
WO2004069189A3 (fr) Procede pour inventorier les enzymes metabolisant des medicaments
AU2003259222A1 (en) Method of diagnosing alzheimer's disease
WO2004067774A3 (fr) Polymorphismes de nucleotide simple utilises en tant que diagnostics predictifs d'effet indesirable (adr) et d'efficacite d'un medicament
AU2003260356A1 (en) An expert system for clinical outcome prediction
CA2534643A1 (fr) Procedes de detection et d'identification de composes
WO2004069867A3 (fr) Polymorphismes genetiques utilises comme diagnostics predictifs des effets indesirables de medicaments (adr) et de l'efficacite de ceux-ci
WO2003072813A3 (fr) Polymorphismes mononucleotidiques permettant de predire des effets indesirables et l'efficacite de medicaments

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004704556

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004704556

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)